BEBPA EUR Bioassay 2023 -- RNA vaccines, comprising a mRNA encapsulated in a lipid nanoparticle (LNP), are a new modality for rapid development of synthetic prophylactic and therapeutic vaccines.
Cell and gene therapies (CGT) are bringing new options to patients while revolutionizing the future of medicine. As you drive this innovation, we're here to provide the global infrastructure you need combined with the personalized experience you deserve.
When setting out to start a cell or gene therapy program, many biotech and pharmaceutical companies inadvertently assume that the preclinical drug development milestones will be similar to traditional therapies.
Immuno-oncology drug development is inherently complex and requires special considerations across the entire spectrum, from preclinical to commercial support for the approved product.
This white paper provides an engaging background on cell and gene therapies, a look into recent therapeutic applications and future trends in the cell and gene therapy technology space.
This white paper provides the current position on the key cell types and their role in cancer immunotherapies, with a more in-depth focus on chimeric antigen receptor (CAR) T-cell therapies.
With nearly a dozen or more products commercialized globally and approximately 1000 clinical trials underway as of the end of 2018, cell and gene therapies are significant component for drug development.
CPI RNA Vaccines 2023 -- A vaccine against Marburg virus is being developed using a self-amplifying messenger RNA (sa mRNA) for the Marburg Glycoprotein (MARV GP) antigen. The vaccine comprises the sa mRNA encapsulated into a lipid nanoparticle (LNP) for protection of the RNA and cellular delivery.
CPI RNA Vaccines 2023 -- Marburg virus infection causes haemorrhagic fever with fatality rates of up to 88%. Provision of a vaccine to Marburg virus is an unmet medical need.
